CoChat

Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice

Open access

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

RATIONALE: Abnormal oscillatory activity associated with N-methyl-D-aspartate (NMDA) receptor hypofunction is widely considered to contribute to the symptoms of schizophrenia. OBJECTIVE: This study aims to characterise the changes produced by NMDA receptor antagonists and antipsychotics on accumbal high-frequency oscillations (HFO; 130-180 Hz) in mice. METHODS: Local field potentials were recorded from the nucleus accumbens of freely moving mice. RESULTS: Systemic injection of ketamine and MK801 both dose-dependently increased the power of HFO and produced small increases in HFO frequency. The atypical antipsychotic drug, clozapine, produced a robust dose-dependent reduction in the frequency of MK801-enhanced HFO, whilst haloperidol, a typical antipsychotic drug, had little effect. Stimulation of NMDA receptors (directly or through the glycine site) as well as activation of 5-HT1A receptors, reduced the frequency of MK801-enhanced HFO, but other receptors known to be targets for clozapine, namely 5-HT2A, 5-HT7 and histamine H3 receptors had no effect. CONCLUSIONS: NMDA receptor antagonists and antipsychotics produce broadly similar fundamental effects on HFO, as reported previously for rats, but we did observe several notable differences. In mice, HFO at baseline were weak or not detectable unlike rats. Post-injection of NMDA receptor antagonists HFO was also weaker but significantly faster. Additionally, we found that atypical antipsychotic drugs may reduce the frequency of HFO by interacting with NMDA and/or 5-HT1A receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-015-4073-0

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NMDA receptor antagonists dose-dependently increase the power and frequency of HFO in the mouse NAc. a Accumbal LFP expressed as spectrograms showing the effect of intraperitoneal injection of 25 mg/kg ketamine. b, c Time courses showing the effect of different doses of ketamine (5, 25, 50 mg/kg, N = 4) on the power and frequency of HFO. d Accumbal LFP expressed as spectrograms showing the effect of intraperitoneal injection of 0.25 mg/kg MK801. e, f Time courses showing the effect of different doses of MK801 (0.01, 0.1, 0.25, 0.5 mg/kg, N = 5) on the power and frequency of HFO. Saline was used as vehicle in both instances. Arrows indicate time of injection. Values are mean ± SEM
Fig. 1 NMDA receptor antagonists dose-dependently increase the power and frequency of HFO in the mouse NAc. a Accumbal LFP expressed as spectrograms showing the effect of intraperitoneal injection of 25 mg/kg ketamine. b, c Time courses showing the effect of different doses of ketamine (5, 25, 50 mg/kg, N = 4) on the power and frequency of HFO. d Accumbal LFP expressed as spectrograms showing the effect of intraperitoneal injection of 0.25 mg/kg MK801. e, f Time courses showing the effect of different doses of MK801 (0.01, 0.1, 0.25, 0.5 mg/kg, N = 5) on the power and frequency of HFO. Saline was used as vehicle in both instances. Arrows indicate time of injection. Values are mean ± SEMCC BY · PubMed Central
Fig. 2 The atypical antipsychotic clozapine dose-dependently decreases the frequency of HFO in the mouse NAc. A1, A2 Example spectrograms taken from the same mouse showing the effect of intraperitoneal injection of clozapine or vehicle on 0.25 mg/kg MK801-enhanced HFO. B Total number of beam breaks after injection of clozapine. C, D Histograms showing the effect of different doses of clozapine (0.2, 1, 5 mg/kg, N = 6) or vehicle on the frequency and power of MK801-enhanced HFO. Values are mean ± SEM for a 10-min period (approximately 50-60 min) post-injection of clozapine and indicated by the shaded area shown on the time courses in the right-hand figure. **p < 0.01; ***p < 0.001 compared with vehicle
Fig. 2 The atypical antipsychotic clozapine dose-dependently decreases the frequency of HFO in the mouse NAc. A1, A2 Example spectrograms taken from the same mouse showing the effect of intraperitoneal injection of clozapine or vehicle on 0.25 mg/kg MK801-enhanced HFO. B Total number of beam breaks after injection of clozapine. C, D Histograms showing the effect of different doses of clozapine (0.2, 1, 5 mg/kg, N = 6) or vehicle on the frequency and power of MK801-enhanced HFO. Values are mean ± SEM for a 10-min period (approximately 50-60 min) post-injection of clozapine and indicated by the shaded area shown on the time courses in the right-hand figure. **p < 0.01; ***p < 0.001 compared with vehicleCC BY · PubMed Central
Fig. 3 The typical antipsychotic haloperidol does not reduce the frequency or power of HFO in the mouse NAc. a Example spectrogram from a representative mouse showing the effect of 1.5 mg/kg i.p. haloperidol on 0.25 mg/kg MK801-enhanced HFO. b Time courses showing the frequency of MK801-enhanced HFO before and after injection of haloperidol or vehicle (N = 10). Arrows indicate injection of MK801and haloperidol, respectively. c Average power of MK801-enhanced HFO after injection of haloperidol or vehicle. d Total number of beam breaks after injection of haloperidol was evaluated in four of the mice. Values are mean ± SEM. **p < 0.01 compared with vehicle
Fig. 3 The typical antipsychotic haloperidol does not reduce the frequency or power of HFO in the mouse NAc. a Example spectrogram from a representative mouse showing the effect of 1.5 mg/kg i.p. haloperidol on 0.25 mg/kg MK801-enhanced HFO. b Time courses showing the frequency of MK801-enhanced HFO before and after injection of haloperidol or vehicle (N = 10). Arrows indicate injection of MK801and haloperidol, respectively. c Average power of MK801-enhanced HFO after injection of haloperidol or vehicle. d Total number of beam breaks after injection of haloperidol was evaluated in four of the mice. Values are mean ± SEM. **p < 0.01 compared with vehicleCC BY · PubMed Central
Fig. 4 Glycine reduces the frequency and power of MK801-enhanced HFO in mice. a, b Histograms showing the effect of 2 g/kg glycine or saline on the frequency and power of MK801-enhanced HFO. Values are mean ± SEM for a 10-min period (approximately 50–60 min) post-injection of glycine and indicated by the shaded area shown on the time courses in the right-hand figure (N = 7). c LFP expressed as a spectrogram from a representative mouse. d Total number of beam breaks post-injection of glycine or saline. Glycine reduces MK801-induced hyperlocomotion. *p < 0.05; **p < 0.01 compared with vehicle
Fig. 4 Glycine reduces the frequency and power of MK801-enhanced HFO in mice. a, b Histograms showing the effect of 2 g/kg glycine or saline on the frequency and power of MK801-enhanced HFO. Values are mean ± SEM for a 10-min period (approximately 50–60 min) post-injection of glycine and indicated by the shaded area shown on the time courses in the right-hand figure (N = 7). c LFP expressed as a spectrogram from a representative mouse. d Total number of beam breaks post-injection of glycine or saline. Glycine reduces MK801-induced hyperlocomotion. *p < 0.05; **p < 0.01 compared with vehicleCC BY · PubMed Central
Fig. 5 NMDA reduces the frequency of MK801-enhanced HFO in mice. a Histogram showing the effect of 70 mg/kg NMDA or saline on the frequency of MK801-enhanced HFO (N = 7). Values are mean ± SEM for a 10-min period approximately 10–20 min post-injection of NMDA and indicated by the shaded area shown on the time courses in the right-hand figure. This experiment was conducted using mice from the glycine study; therefore, control values shown are those from Fig. 4. b LFP expressed as a spectrogram from a representative mouse. **p < 0.01 compared with vehicle
Fig. 5 NMDA reduces the frequency of MK801-enhanced HFO in mice. a Histogram showing the effect of 70 mg/kg NMDA or saline on the frequency of MK801-enhanced HFO (N = 7). Values are mean ± SEM for a 10-min period approximately 10–20 min post-injection of NMDA and indicated by the shaded area shown on the time courses in the right-hand figure. This experiment was conducted using mice from the glycine study; therefore, control values shown are those from Fig. 4. b LFP expressed as a spectrogram from a representative mouse. **p < 0.01 compared with vehicleCC BY · PubMed Central
Fig. 6 Stimulation of 5-HT1A receptors produces a short-lasting reduction in HFO. a, b Frequency and power of MK801-enhanced HFO (average 60 min) post-injection of 1.0 mg/kg 8-OH-DPAT (5-HT1A agonist), 1.0 mg/kg MDL 11939 (5-HT2A antagonist), 1.0 mg/kg SB269970 (5-HT7 antagonist) and 5.0 mg/kg BF2649 (H3 inverse agonist). These compounds mimic some of the different pharmacological activities of clozapine at specific receptor targets (N = 5–6/group). Values are mean ± SEM. c Time course showing the effect of intraperitoneal injection of the potent 5-HT1A agonist 8-OH-DPAT on the frequency of MK801-enhanced HFO. First arrow indicates injection of 0.25 mg/kg MK801; second arrow indicates injection of 8-OH-DPAT or vehicle. ***p < 0.001
Fig. 6 Stimulation of 5-HT1A receptors produces a short-lasting reduction in HFO. a, b Frequency and power of MK801-enhanced HFO (average 60 min) post-injection of 1.0 mg/kg 8-OH-DPAT (5-HT1A agonist), 1.0 mg/kg MDL 11939 (5-HT2A antagonist), 1.0 mg/kg SB269970 (5-HT7 antagonist) and 5.0 mg/kg BF2649 (H3 inverse agonist). These compounds mimic some of the different pharmacological activities of clozapine at specific receptor targets (N = 5–6/group). Values are mean ± SEM. c Time course showing the effect of intraperitoneal injection of the potent 5-HT1A agonist 8-OH-DPAT on the frequency of MK801-enhanced HFO. First arrow indicates injection of 0.25 mg/kg MK801; second arrow indicates injection of 8-OH-DPAT or vehicle. ***p < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 20

Metadata

Authors
Hunt, M. J., Olszewski, M., Piasecka, J., Whittington, M. A., & Kasicki, S.
Affiliations
  • Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
  • University of York (GB)
Corresponding author
Hunt, Mark J.
Venue
Psychopharmacology
Published
2015-10-08
Volume
232
Issue
24
Pages
4525-4535
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W1956040624
Cited by
20
References
61
Citations by year
2025: 2 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1
FWCI
1.35
Type
journal article
Language
en
Open access
Locations
  • Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Wellcome Trust (098352/Z/12/Z, 098352)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
NMDA receptor antagonists, antipsychotic drugs, high-frequency oscillations, nucleus accumbens, ketamine, MK-801, clozapine, haloperidol, 5-HT1A receptor, NMDA receptor glycine site, schizophrenia, local field potentials, freely moving mice
MeSH terms
Animals, Clozapine, Dose-Response Relationship, Drug, Haloperidol, Ketamine, Male, Nucleus Accumbens, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Dizocilpine Maleate, Rats, Wistar, Excitatory Amino Acid Antagonists, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice. https://app.cochat.ai/papers/10.1007/s00213-015-4073-0
The paper
Hunt, M. J., Olszewski, M., Piasecka, J., Whittington, M. A., & Kasicki, S. (2015). Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice. Psychopharmacology. https://doi.org/10.1007/s00213-015-4073-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.